Paul Jason Cockle

Title: Paul Jason Cockle: Innovator in Cancer Vaccine Development

Introduction

Paul Jason Cockle is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of cancer research, particularly in the development of innovative cancer vaccines. With a total of 2 patents, his work focuses on immunogenic TAA polypeptides and their applications in cancer treatment.

Latest Patents

Cockle's latest patents revolve around cancer vaccines. The present disclosure provides (i) isolated immunogenic TAA polypeptides, including immunogenic MUC1 polypeptides, immunogenic MSLN polypeptides, and immunogenic TERT polypeptides. It also includes (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to the uses of the polypeptides, nucleic acid molecules, and compositions.

Career Highlights

Cockle is currently associated with Pfizer Corporation, where he continues to advance his research in cancer vaccines. His work has the potential to significantly impact cancer treatment and improve patient outcomes.

Collaborations

Some of his notable coworkers include Joseph John Binder and Derek John Falconer. Their collaborative efforts contribute to the innovative research environment at Pfizer Corporation.

Conclusion

Paul Jason Cockle is a distinguished inventor whose work in cancer vaccine development showcases his commitment to advancing medical science. His contributions are paving the way for new treatment options in oncology.